A Phase 1, Open-Label, Randomized, Single Dose, 5-Period, 5-Treatment Study to Evaluate the Relative Bioavailability and Effect of Food on TAK-831 Tablet Formulations in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2019
At a glance
- Drugs TAK 831 (Primary)
- Indications Ataxia; Friedreich's ataxia; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Takeda Oncology
- 07 Jan 2019 Status changed from recruiting to completed.
- 25 Oct 2018 Planned End Date changed from 15 Dec 2018 to 22 Dec 2018.
- 25 Oct 2018 Planned primary completion date changed from 15 Dec 2018 to 22 Dec 2018.